2 April 2024
Cambridge Cognition Holdings plc
("Cambridge Cognition", the "Company" or the "Group")
Total Voting Rights and Block Listing Return
Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, announces that pursuant to its block admission facility, details of which were announced on 21 March 2023, it has recently issued 189,263 new ordinary shares in the Company in satisfaction of the exercise of employee share options. Accordingly, as at 31 March 2024 the Company has 35,149,372 ordinary shares in issue.
There are no shares held in treasury therefore the total number of voting rights in the Company is 35,149372. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in Cambridge Cognition under the FCA's Disclosure and Transparency Rules.
Block Listing Return
The Company also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
| Name of applicant: | Cambridge Cognition Holdings plc | |||
| Name of scheme: | Share Options | |||
| Period of return: | From: | 1 October 2023 | To: | 31 March 2024 |
| Number and class of share(s) (amount of stock / debt securities) originally listed and the date of admission: | 1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on 23 March 2023 | |||
| Balance of unallotted securities under scheme(s) from previous return: | 762,855 ordinary shares | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | Nil | |||
| Less: Number of securities issued/allotted under scheme(s) during period: | 296,539 ordinary shares | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 466,316 ordinary shares | |||
| Name of contact: | Stephen Symonds |
| Telephone number of contact: | +44 (0)1223 810700 |
Enquiries:
| |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.